NasdaqGS:INCYBiotechs
Incyte’s Zynyz Wins CHMP Support As Investors Weigh Valuation And Earnings
Incyte's drug Zynyz received a positive opinion from the European Medicines Agency's CHMP for use with chemotherapy as a first line treatment for metastatic or inoperable squamous cell carcinoma of the anal canal.
The recommendation supports potential use of Zynyz in adult patients across the European Union, subject to final regulatory approval.
For investors watching NasdaqGS:INCY, this regulatory progress comes with the stock trading at $100.05 and a 1 year return of 50.8%. Over 3 and 5...